M

Moderna

Develops mRNA-based medicines for health

Senior Director of New Product Planning - Oncology

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • A bachelor's degree or higher in a scientific, medical, business, or related field.
  • At least 10 years of experience in the pharmaceutical or biotechnology industry, including significant experience in new product planning, research strategy, program leadership, global marketing, portfolio strategy, or a related function.
  • Demonstrated experience leading product and portfolio strategy across multiple programs in discovery and early clinical development, including influencing senior decisions on program advancement, investment, and resource allocation.
  • Strong understanding of oncology biology and clinical development, with the ability to independently evaluate mechanistic, translational, and clinical evidence and connect it to treatment decisions.

Responsibilities

  • Develop a deep understanding of Moderna’s platform and its application to oncology.
  • Work with scientific and clinical colleagues to assess how each program’s mechanism of action could affect disease, including the implications of tumor biology, patient heterogeneity, and biomarkers.
  • Independently evaluate mechanistic, translational, and clinical evidence and its implications for program strategy, including disease progression and clinical endpoints.
  • Engage directly with scientific evidence and external experts to evaluate competing hypotheses and identify unresolved biological questions that affect development choices.
  • Understand how patients move through diagnosis, staging, biomarker testing, treatment selection, assessment, and subsequent treatment. Identify who makes each decision and how clinical evidence, physician judgment, patient preferences, and access shape those choices, including unmet needs within current standards of care.
  • Integrate market and competitive expertise into early program decisions.
  • Evaluate approved therapies, emerging mechanisms, and competitor programs, including their clinical evidence, development timelines, and potential strengths and limitations.
  • Develop scenarios for how standards of care and treatment pathways may evolve, including changes in treatment sequencing and the requirements for future differentiation.
  • Use direct conversations with key opinion leaders, treating physicians, and other internal and external experts, together with scientific and market evidence, to test program assumptions and resolve questions that affect development choices.
  • Lead a disciplined strategy process with program teams: frame the choices, identify the information needed, structure debate around alternatives and tradeoffs, and make the logic for program decisions explicit.
  • Apply a biotech investment mindset to program development, identifying the most efficient path to reduce key risks and reach proof of concept. Define the evidence needed to justify further investment and adapt recommendations as data emerge.
  • Shape strategy and prioritization across the early oncology portfolio. Develop and present recommendations to senior leaders on which opportunities to advance and where to focus investment and resources, with clear alternatives, tradeoffs, and evidence gaps.
  • Integrate scientific, disease, market, and competitive insights to define where each oncology program can succeed and prioritize indications, patient populations, treatment settings, and lines of therapy.
  • Develop and refine target product profiles with program teams that connect the program’s mechanism of action and disease biology to a defined patient population, treatment setting, and clinical benefit. Define the efficacy, safety, durability, and dosing and administration requirements, together with the supporting evidence, needed for differentiation and to change treatment choices as standards of care evolve.
  • Shape clinical and evidence-generation plans, including patient selection, biomarkers, endpoints, and the evidence required for regulatory approval, physician adoption, reimbursement, and access.

Desired Qualifications

  • Experience in oncology, including familiarity with treatment pathways, clinical endpoints, patient segmentation, and the evolving competitive landscape.
  • Strong analytical skills and the ability to build, challenge, and communicate assumptions.
  • Demonstrated ability to use artificial intelligence-supported evidence workflows to investigate program questions, test competing explanations, evaluate underlying sources, and identify when expert input or additional data is needed.
  • Strong written and verbal communication skills, including the ability to present a concise recommendation to senior leaders and defend it objectively.
  • The ability to influence across functions without direct authority, lead teams through competing views, and establish productive working relationships with scientific, clinical, and commercial colleagues.

About the Company

Moderna

Develops mRNA-based medicines for health

Moderna develops medicines built on messenger RNA (mRNA). Its products use mRNA delivered into cells to instruct them to produce specific proteins that can prevent or treat disease, with vaccines being a primary example. In practice, a dose delivers engineered mRNA into the body, cells translate it into a target protein, and the immune system responds or the protein modulates biology to combat disease. Moderna differentiates itself through its focus on building a whole mRNA medicines platform and in-house capabilities for designing, manufacturing, and scaling mRNA therapies, including rapid development and large-scale production. Its goal is to create a new category of medicines based on mRNA that can improve how diseases are discovered, developed, and treated, ultimately improving patient outcomes.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2010

Recently Posted Jobs

Explore more opportunities at Moderna

See more jobs